Citigroup Maintains Buy on Cogent Biosciences, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz has maintained a Buy rating on Cogent Biosciences (COGT) and increased the price target from $11 to $13.
February 26, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on Cogent Biosciences and raised the price target from $11 to $13.
The upgrade in the price target by a reputable analyst like David Lebowitz from Citigroup is a strong positive signal for investors, indicating a bullish outlook on the stock. This is likely to increase investor confidence and could lead to a short-term price increase for COGT.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100